Advertisement

No reason to stop drug trials despite death: French minister

The Local France
The Local France - [email protected]
No reason to stop drug trials despite death: French minister
Photo: e-Magine Art/Flickr

There is no reason to stop medicine trials in France, the country's health minister said Monday, despite the death of a man during testing for a new drug.

Advertisement

"There is a major problem - massive, unprecedented in France - and we must understand what happened, but there is nothing to justify stopping clinical trials," Marisol Touraine told France's RTL radio.
   
Touraine voiced concern that she was only informed of the accident four days after the patient - who later died - was rushed to hospital.
   
"A quicker alert would have been appreciated," she said.
   
"Faced with such a serious situation, we would expect the laboratory to approach the health authorities more quickly."
Six people were hospitalized after taking part in a Phase I trial for a new pain and mood disorder medication being tested by French laboratory Biotrial on behalf of Portuguese pharmaceutical company Bial.
   
One died on Sunday after being rendered brain dead. The other five, aged 28 to 49, were said to be in a stable condition.
   
A total of 108 volunteers took part in the trial, 90 of whom received the drug at varying doses while the rest were given placebos. Those hospitalized had received the highest dose.
  
Three separate probes have been launched to determine whether the tragedy was caused by a procedural error or by the substance.
   
Biotrial, which has been carrying out drug trials since 1989, said Sunday that the situation is "even more upsetting given that there is as yet no explanation".
   

More

Join the conversation in our comments section below. Share your own views and experience and if you have a question or suggestion for our journalists then email us at [email protected].
Please keep comments civil, constructive and on topic – and make sure to read our terms of use before getting involved.

Please log in to leave a comment.

See Also